Current Edition


New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent® (dupilumab) improved moderate-to-severe asthma

Results showed Dupixent demonstrated a significant improvement in multiple asthma endpoints in two Phase 3 clinical trials in a broad population of patients with uncontrolled …

Continue Reading →

Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis

U.S. regulatory submission for patients ages 12-17 planned for third quarter 2018 A pivotal Phase 3 trial evaluating Dupixent® (dupilumab) to treat moderate-to-severe atopic dermatitis …

Continue Reading →